Literature DB >> 11095402

Erythropoietin receptor expression in human melanoma cells.

E Selzer1, V Wacheck, R Kodym, H Schlagbauer-Wadl, W Schlegel, H Pehamberger, B Jansen.   

Abstract

Erythropoietin is well known for its role in the control of erythropoiesis, where it acts by binding to its cognate receptor (EpoR) on the surface of erythroid progenitor cells. Here we present the novel finding that the EpoR is also expressed in cells of the melanocytic lineage. It is expressed in transformed cell lines established from normal melanocytes and also in established human melanoma cell lines derived from melanoma metastases, but not in normal primary human melanocytes. The analysis of individual subclones isolated from spontaneously transformed melanocytes revealed that approximately 50% of all the clones examined expressed the EpoR. Further analysis of the individual growth characteristics of EpoR-positive and EpoR-negative clones indicated that, under standard cell culture conditions, expression of the receptor did not affect cell growth. Expression of this receptor is consequently most likely driven by an event that is associated with, but not absolutely required for, the transformed phenotype. While the definite function of this receptor in melanoma cells is still unknown and additional studies are required, our findings support the hypothesis that the EpoR may serve as a progression marker for human melanoma. This observation might be useful in the early diagnosis of melanoma.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11095402     DOI: 10.1097/00008390-200010000-00003

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  18 in total

1.  The value of serum levels of IL-6, TNF-alpha, and erythropoietin in metastatic malignant melanoma: serum IL-6 level is a valuable prognostic factor at least as serum LDH in advanced melanoma.

Authors:  Faruk Tas; Hilal Oguz; Andaç Argon; Derya Duranyildiz; Hakan Camlica; Vildan Yasasever; Erkan Topuz
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

Review 2.  Association between pharmaceutical support and basic science research on erythropoiesis-stimulating agents.

Authors:  Charles L Bennett; Stephen Y Lai; Michael Henke; Sara E Barnato; James O Armitage; Oliver Sartor
Journal:  Arch Intern Med       Date:  2010-09-13

3.  Pleiotrophic actions of erythropoietin.

Authors:  Laurie Feldman; Arthur J Sytkowski
Journal:  Environ Health Prev Med       Date:  2003-01       Impact factor: 3.674

4.  Expression and functional significance of the erythropoietin receptor in hepatocellular carcinoma.

Authors:  Milljae Shin; Doopyo Hong; Zhengyun Zhang; You Min Kim; Wookjong Lee; Jae-Won Joh; Sung-Joo Kim
Journal:  HPB (Oxford)       Date:  2013-03-15       Impact factor: 3.647

Review 5.  Supportive care for patients with early breast cancer.

Authors:  Laura García-Estévez; Ignasi Tusquets; Isabel Alvarez; César Rodríguez; Yolanda Fernández; Miguel Angel Seguí; Jesús García-Mata; Ana Lluch
Journal:  Clin Transl Oncol       Date:  2010-01       Impact factor: 3.405

6.  Impact of erythropoietin on the effects of irradiation under hypoxia.

Authors:  Cristiana Lo Nigro; Monica Maffi; Jean Louis Fischel; Martino Monteverde; Paolo Catarsi; Federica Tonissi; Laura Lattanzio; Michela Riba; Marie-Christine Etienne-Grimaldi; Patricia Formento; Gerard Milano; Marco Merlano
Journal:  J Cancer Res Clin Oncol       Date:  2009-06-05       Impact factor: 4.553

Review 7.  Effects of recombinant erythropoietin on breast cancer-initiating cells.

Authors:  Tiffany M Phillips; Kwanghee Kim; Erina Vlashi; William H McBride; Frank Pajonk
Journal:  Neoplasia       Date:  2007-12       Impact factor: 5.715

8.  EPO-R expression patterns in resected gastric adenocarcinoma followed by adjuvant chemoradiation treatment.

Authors:  Maria Sereno; Javier De Castro; Cristóbal Belda-Iniesta; Miguel Angel Garcia-Cabezas; Paloma Cejas; Enrique Casado; Jorge Barriuso; Jaime Feliu; Javier Larrauri
Journal:  Pathol Oncol Res       Date:  2008-11-11       Impact factor: 3.201

9.  Clinical significance of erythropoietin receptor expression in oral squamous cell carcinoma.

Authors:  Yu-Tsai Lin; Hui-Ching Chuang; Chang-Han Chen; Gian Luca Armas; Han-Ku Chen; Fu-Min Fang; Chao-Cheng Huang; Chih-Yen Chien
Journal:  BMC Cancer       Date:  2012-05-28       Impact factor: 4.430

10.  Recombinant human erythropoietin promotes the acquisition of a malignant phenotype in head and neck squamous cell carcinoma cell lines in vitro.

Authors:  Eric Abhold; Elham Rahimy; Jessica Wang-Rodriguez; Katherine J Blair; Michael A Yu; Kevin T Brumund; Robert A Weisman; Weg M Ongkeko
Journal:  BMC Res Notes       Date:  2011-12-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.